1

Brain functional network integrity sustains cognitive function despite atrophy in presymptomatic genetic frontotemporal dementia.

Kamen A. Tsvetanov,[*,1,2] Stefano Gazzina,[*,1,3] Simon P. Jones,[1] John van Swieten,[3] Barbara Borroni,[4] Raquel Sanchez-Valle,[5] Fermin Moreno,[6, 7] Robert Laforce Jr,[8] Caroline Graff,[9] Matthis Synofzik,[10,11] Daniela Galimberti,[12,13] Mario Masellis,[14] Maria Carmela Tartaglia,[15] Elizabeth Finger,[16] Rik Vandenberghe,[17,18] Alexandre de Mendonça,[19] Fabrizio Tagliavini,[20] Isabel Santana,[21,22,23] Simon Ducharme,[24,25] Chris Butler,[26] Alex Gerhard,[27] Adrian Danek,[28] Johannes Levin,[28] Markus Otto,[29] Giovanni Frisoni,[30,31] Roberta Ghidoni,[32] Sandro Sorbi,[33,34] Jonathan D. Rohrer,[35] and James B. Rowe,[1,2,36] on behalf of the Genetic FTD Initiative, GENFI.[#]

[*]Joint first authorship

Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK

Cambridge Centre for Ageing and Neuroscience (Cam-CAN), University of Cambridge and MRC Cognition and Brain Sciences Unit, Cambridge, UK

Department of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands

Centre for Neurodegenerative Disorders, Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy

Alzheimer's disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic, Institut d'Investigacións Biomèdiques August Pi I Sunyer, University of Barcelona, Barcelona, Spain

Cognitive Disorders Unit, Department of Neurology, Hospital Universitario Donostia, San Sebastian, Gipuzkoa, Spain

Neuroscience Area, Biodonostia Health Research Insitute, San Sebastian, Gipuzkoa, Spain

Clinique Interdisciplinaire de Mémoire, Département des Sciences Neurologiques, CHU de Québec, and Faculté de Médecine, Université Laval, Québec, Canada

Karolinska Institutet, Department NVS, Center for Alzheimer Research, Division of Neurogenetics, Stockholm, Sweden

Department of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research & Center of Neurology, University of Tübingen, Germany

German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany

29  *12 University of Milan, Centro Dino Ferrari, Milan, Italy*

30  *13 Fondazione IRCSS Ca' Granda, Ospedale Maggiore Policlinico, Neurodegenerative Diseases Unit, Milan, Italy*

31  *14 LC Campbell Cognitive Neurology Research Unit, Sunnybrook Research Institute, Toronto, Ontario, Canada*

32  *15 Toronto Western Hospital, Tanz Centre for Research in Neurodegenerative Disease, Toronto, Ontario, Canada*

33  *16 Department of Clinical Neurological Sciences, University of Western Ontario, London, ON, Canada*

34  *17 Laboratory for Cognitive Neurology, Department of Neurosciences, KU Leuven, Leuven, Belgium*

35  *18 Neurology Service, University Hospitals Leuven, Belgium, Laboratory for Neurobiology, VIB-KU*

36  *19 Laboratory of Neurosciences, Institute of Molecular Medicine, Faculty of Medicine, University of Lisbon, Lisbon,*
37 *Portugal*

38  *20 Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Neurologico Carlo Besta, Milan, Italy*

39  *21 Neurology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal*

40  *22 Faculty of Medicine, University of Coimbra, Coimbra, Portugal*

41  *23 Centre of Neurosciences and Cell biology, Universidade de Coimbra, Coimbra, Portugal*

42  *24 Department of Psychiatry, McGill University Health Centre, McGill University, Montreal, Canada*

43  *25 McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, Canada*

44  *26 Nuffield Department of Clinical Neurosciences, Medical Sciences Division, University of Oxford, Oxford, UK*

45  *27 Faculty of Medical and Human Sciences, Institute of Brain, Behaviour and Mental Health, The University of Manchester,*
46 *Withington, Manchester, UK*

47  *28 Neurologische Klinik und Poliklinik, Ludwig-Maximilians-Universität, Munich, German Center for Neurodegenerative*
48 *Diseases (DZNE), Munich, Germany*

49  *29 Department of Neurology, University Hospital Ulm, Ulm, Germany*

50  *30 Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia,*
51 *Italy*

52  *31 Memory Clinic and LANVIE-Laboratory of Neuroimaging of Aging, University Hospitals and University of Geneva,*
53 *Geneva, Switzerland*

54  *32 Molecular Markers Laboratory, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy*

33 Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy

34 Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) "Don Gnocchi", Florence, Italy

35 Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square,
London, UK

36 Medical Research Council Cognition and Brain Sciences Unit, Cambridge, UK

 # See Appendix for a list of GENFI consortium members.

Correspondence to:

Kamen A. Tsvetanov

e-mail: kat35@cam.ac.uk

Keywords (up to five): frontotemporal dementia (FTD), presymptomatic, functional magnetic resonance imaging (*f*MRI), network connectivity.

Abstract

INTRODUCTION: The presymptomatic phase of neurodegenerative disease can last many years, with sustained cognitive function despite progressive atrophy. We investigate this phenomenon in familial Frontotemporal dementia (FTD).

METHODS: We studied 121 presymptomatic FTD mutation carriers and 134 family members without mutations, using multivariate data-driven approach to link cognitive performance with both structural and functional magnetic resonance imaging. Atrophy and brain network connectivity were compared between groups, in relation to the time from expected symptom onset.

RESULTS: There were group differences in brain structure and function, in the absence of differences in cognitive performance. Specifically, we identified behaviourally-relevant structural and functional network differences. Structure-function relationships were similar in both groups, but coupling between functional connectivity and cognition was stronger for carriers than for non-carriers, and increased with proximity to the expected onset of disease.

DISCUSSION: Our findings suggest that maintenance of functional network connectivity enables carriers to maintain cognitive performance.

1. Introduction

Across the adult healthy lifespan, the structural and functional properties of brain networks are coupled, and both are predictive of cognitive ability [1,2]. The connections between structure, function and performance have been influential in developing current models of ageing and neurodegeneration [3–5]. However, this work contrasts with the emerging evidence of neuropathological and structural changes many years before the onset of symptoms of Alzheimer's disease and frontotemporal dementia (FTD) [6–8]. Genetic FTD with highly-penetrant gene mutations provides the opportunity to examine the precursors of symptomatic disease. Three main genes account for 10-20% of FTD cases: chromosome 9 open reading frame 72 (*C9orf72*), granulin (*GRN*) and microtubule-associated protein tau (*MAPT*). These genes vary in their phenotypic expression and in the age of onset [9]. Despite pleiotropy [10], environmental and secondary genetic moderation [11,12] all three mutations cause significant structural brain changes in key regions over a decade before the expected age of disease onset [7,13], confirmed by longitudinal studies [14,15].

The divergence between early structural change and late cognitive decline begs the question: how do presymptomatic gene carriers stay so well in the face of progressive atrophy? We propose that the answer lies in the maintenance of network dynamics and functional organisation [16]. Across the lifespan, functional brain network connectivity predicts cognitive status [17], and this connectivity-cognition relationship becomes stronger with age [18,19].

Our overarching hypothesis is that for those at genetic risk of dementia, the maintenance of network connectivity prevents the manifestation of symptoms despite progressive structural changes. A challenge is that neither the anatomical and functional substrates of cognition nor the targets of neurodegenerative disease are mediated by single brain regions: they are distributed across multi-level and interactive networks. We therefore used a multivariate data-driven approach to identify differences in the multidimensional brain-behaviour relationship between presymptomatic carriers and non-carriers of mutations in FTD genes. We identified key brain networks [20] from a large independent population-based age-matched dataset [21].

We tested three key hypotheses: (i) presymptomatic carriers differ from non-carriers in brain structure and brain function, but not in cognitive function, (ii) brain structure and function correlate with performance in

111 both groups, but functional network indices are stronger predictors of cognition in carriers, and (iii) the

112 dependence on network integrity for maintaining cognitive functioning increases as carriers approach the

113 onset of symptoms.

2. Methods

2.1. Participants

Thirteen research sites across Europe and Canada recruited participants as part of an international

multicentre partnership, the Genetic Frontotemporal Initiative (GENFI). 313 participants had usable

structural and resting state functional magnetic resonance imaging data (MRI) [7,13]. The study was

approved by the institutional review boards for each site, and participants providing written informed

consent. Five participants were excluded due to excessive head motion (see below), resulting in 308

datasets for further analysis.

Participants were genotyped based on whether they carried a pathogenic mutation in *MAPT, GRN* and

C9orf72. In this study, we focus on non-carriers (NC, N=134) and presymptomatic carriers (PSC, N=121), i.e.

gene carriers with normal cognitive function based on a neurocognitive assessment (see below).

Participants and site investigators were blinded to the research genotyping, although a minority of

participants had undergone predictive testing outwith the GENFI study. See Table 1 for demographic

information of both groups. In keeping with other GENFI reports, the years to expected onset (EYO) were

calculated as the difference between age at assessment and mean age at onset within the family [7].

2.2. Neurocognitive assessment

Each participant completed a standard clinical assessment consisting of medical history, family history,

functional status and physical examination, in complement with collateral history from a family member or

a close friend. In the current study 13 behavioural measures of cognitive function were correlated with

neuroimaging measures. These included the Uniform Data Set [22]: the Logical Memory subtest of the

Wechsler Memory Scale-Revised with Immediate and Delayed Recall scores, Digit Span forwards and

backwards from the Wechsler Memory Scale-Revised, a Digit Symbol Task, Parts A and B of the Trail Making

Test, the short version of the Boston Naming Test, and Category Fluency (animals). Additional tests included

three subscores of the Letter Fluency and Wechsler Abbreviated Scale of Intelligence Block Design task,

and the Mini-Mental State Examination. Latency measures for the Trail Making Test were inverted so that

higher values across all tests reflect better performance.

2.3. Neuroimaging assessment

Figure 1 provides a schematic representation of imaging data processing pipeline and the analysis strategy for linking brain-behaviour data. MRI data were acquired using 3T scanners and 1.5T where no 3T scanning was available from various vendors, with optimised scanning protocols to maximise synchronisation across scanners and sites [7,13]. A 3D-structural MRI was acquired on each participant using T1-weighted Magnetic Prepared Rapid Gradient Echo sequence. The co-registered T1 images were segmented to extract probabilistic maps of 6 tissue classes: grey matter (GM), white matter (WM), cerebrospinal fluid (CSF), bone, soft tissue, and residual noise. The native-space GM and WM images were submitted to diffeomorphic registration to create equally represented gene-group template images [DARTEL; 23]. The templates for all tissue types were normalised to the Montreal Neurological Institute template using a 12-parameter affine transformation. The normalised images were smoothed using an 8-mm Gaussian kernel.

For resting state fMRI measurements, Echo-Planar Imaging data were acquired with at least six minutes of scanning. The imaging data were analysed using Automatic Analysis [AA 4.0; ,24] pipelines and modules which called relevant functions from SPM12 [25]. To quantify the total motion for each participant, the root mean square volume-to-volume displacement was computed using the approach of Jenkinson et al [26]. Participants with 3.5 or more standard deviations above the group mean motion displacement were excluded from further analysis (N = 5). To further ensure that potential group bias in head motion did not affect later analysis of connectivity, we took three further steps: i) fMRI data was further postprocessed using whole-brain Independent Component Analysis (ICA) of single subject time-series denoising, with noise components selected and removed automatically using *a priori* heuristics using the ICA-based algorithm [27], ii) postprocessing of network node time-series (see below) and iii) a subject-specific estimate of head movement for each participant [26] included as a covariate in group-level analysis [28].

2.4. Network definition

The location of the key cortical regions in each network was identified by spatial-ICA in an independent dataset of 298 age-matched healthy individuals from a large population-based cohort [21]. Full details about preprocessing and node definition are described previously [29]. Four networks commonly affected by neurodegenerative diseases including FTD [20] were identified by spatially matching to pre-existing templates [30]. The node time-series were defined as the first principal component resulting from the

singular value decomposition of voxels in an 8-mm radius sphere, which was centred on the peak voxel for
each node [18]. Visual representation of the spatial distribution of the nodes is shown in Figure 2.

We aimed to further reduce the effects of noise confounds on functional connectivity effects of node time-
series using general linear model (GLM) [28]. This model included linear trends, expansions of realignment
parameters, as well as average signal in WM and CSF, including their derivative and quadratic regressors
from the time-courses of each node. The WM and CSF signals were created by using the average signal
across all voxels with corresponding tissue probability larger than 0.7 in associated tissue probability maps
available in SPM12. A band-pass filter (0.0078-0.1 Hz) was implemented by including a discrete cosine
transform set in the GLM. Finally, the functional connectivity (FC) between each pair of nodes was
computed using Pearson's correlation on postprocessed time-series.

2.5. Statistical analysis

2.5.1. Group differences in brain structure, function and cognition

To assess the group-differences in neuroimaging and behavioural dataset we used multiple linear
regression with a well-conditioned shrinkage regularization [31,32] and 10-Fold Cross–Validation [33]. In
the analysis of brain structure we used as independent variables the mean grey matter volume (GMV) of
246 brain nodes [34]. In the analysis of brain function, we used the functional connectivity between 15
nodes, which were part of the four large-scale functional networks described above. In the analysis of
cognitive function, the independent variables comprised the performance measures on the 13
neuropsychological tests performed outside of the scanner. In all three analyses the dependent variable
was the genetic status (PSC vs NC) including age as a covariate of no interest. In addition, in the analysis of
neuroimaging data we included scanner site and head motion as additional covariates of no interest.

2.5.2. Brain-behaviour relationships

For the brain-behaviour analysis, we adopted a two-level procedure. In the first-level analysis, we assessed
the multidimensional brain-behaviour relationships using partial least squares [35]. This analysis described
the linear relationships between the two multivariate datasets, namely neuroimaging (either GMV or FC)
and behavioural performance, by providing pairs of latent variables (Brain-LVs and Cognition-LVs) as linear
combinations of the original variables which are optimised to maximise their covariance. Namely, dataset
1 consisted of a brain feature set, which could be either grey matter volume (GMV dataset) or functional

connectivity strength between pairs of regions for each individual (FC dataset). Dataset 2 included the
performance measures on the 13 tests (i.e. Cognition dataset), as considered in the multiple linear
regression analysis of group differences in cognition. Covariates of no interest included head motion,
scanner site, gender and handedness.

Next, we tested whether the identified behaviourally-relevant LVs of brain structure and function were
differentially expressed by NC and PSC as a function of expected years to onset. To this end, we performed
a second-level analysis using multiple linear regression with robust fitting algorithm as implemented in
matlab's function "fitlm.m". Independent variables included subjects' brain scores from first level PLS
(either Structure-LV or Function-LV subject scores), group information, expected years to onset and their
interaction terms (e.g. brain scores x group, brain scores x years to expected onset, etc.). The dependent
variable was subjects' cognitive scores from the first level analysis in the corresponding PLS (Cognition-LV).
Covariates of no interest included gender, handedness, head movement and education (Figure 1).

211 3. Results

212 3.1. Group differences in neuroimaging and cognitive data

213 *Brain structure*

214 The multiple linear regression model testing for overall group differences in grey matter volume between
215 PSC and NC was significant (r=.14, p=.025), reflecting expected presymptomatic differences in brain-wide
216 atrophy. The frontal, parietal and subcortical regions had most atrophy in PSC (Figure 3). As expected, the
217 group difference in grey matter volume of these regions increased as EYO decreased, see Supplementary
218 Materials.

219 *Brain Function*

220 The multiple linear regression model testing for overall group differences in functional connectivity
221 between PSC and NC was marginally significant (r=.12, p=.049). The pattern of connectivity indicated mainly
222 increased connectivity between SN-DMN and SN-FPN in presymptomatic carriers, coupled with decreased
223 connectivity within the networks and DMN-FPN connectivity (Figure 3).

224 *Cognitive Function*

225 We did not identify group differences in cognition and behaviour (r=.002, p=.807), confirming the
226 impression of "healthy" status among presymptomatic carriers. However, in the next section, we consider

227 the relationships between structure, function and cognition that underlie this maintenance of cognitive
228 function.

3.2. Brain-behaviour relationships

Structure-cognition

Partial least squares analysis of grey matter volume and cognition identified one significant pair of latent
variables (r = .40, p = .009). This volumetric latent variable expressed negative loadings in frontal (superior
frontal gyrus, precentral gyrus, paracentral lobule), parietal (postcentral gyrus, precuneus, superior and
inferior parietal lobule) and occipital (lateral and medial occipital cortex) regions and positive loadings in
parahippocampal and hippocampal regions (Figure 4). The Cognition-LV profile expressed positively a large
array of cognitive tests, with strongest values on delayed memory, Trail Making, Digit Symbol, Boston
Naming and Fluency tests. The positive correlation between volumetric and cognitive LV's confirms the
expected relationship across the cohort as a whole, between cortical grey matter volume and both
executive, language and mnemonic function (Figure 4).

To understand the structure-cognition relationship in each group and in relation to the expected
years of onset, we performed a second-level moderation analysis using a regression model: we entered
Cognition-LV subject scores as dependent variable, and grey matter volume LV subject scores, genetic
status (i.e. carrier or non-carrier), expected years to onset and their interactions as independent variables
in addition to covariates of no interest. The results indicated that the relationship between grey matter
volume and cognition could not be explained by genetic status, expected years to onset or their interactions
with grey matter volume LV subject scores. There was no evidence for genetic status- and onset-dependent
differences (over and above ageing and other covariates) in the associations between grey matter volume
and cognition in this analysis (Figure 4).

Connectivity-Cognition

PLS analysis of functional connectivity and cognition also identified one significant pair of LVs (Function-LV
and Cognition-LV, r=.32, p=.020), see Figure 5. This Function-LV reflected weak between-network
connectivity, coupled with strong within-network connectivity. This pattern indicates the segregation or
modularity of large-scale brain networks. The Cognition-LV expressed all tests, with positive loading values
indicating that higher performance on a wide range of cognitive tests is associated with stronger functional
network segregation. Cognitive deficits were associated with loss of segregation, with increased between-
network connectivity and decreased within-network connectivity.

To further test whether the observed behaviourally-relevant pattern of connectivity is differentially
expressed between genetic status groups and expected years of onset, we constructed a second-level
regression model with robust error estimates by including Function-LV subject scores, genetic status,
expected years of onset and their interaction terms as independent variables and Cognition-LV as
dependent variable in addition to covariates of no interest (Figure 5).

We found evidence for significant interaction between expected years of onset and Function-LV (r=.21,
p<.001) and between group and Function-LV (r=.15, p=.003) explaining unique variance in Cognition-LV.
We used the Dawson and Richter approach [36] to test formally for differences in the relationship (i.e.
simple slopes) between Function-LV and Cognition-LV for PSC and NC. The relationship between Function-
LV and Cognition-LV was stronger for PSC relative to NC (r=.15, p=.003), indicating the increasing
importance of functional connectivity between the large-scale networks for PSC participants to maintain
performance (Figure 5).

For ease of interpretation and illustration, we also computed the correlation between Cognition-LV and
Function-LV for high and low levels of expected years to onset (EYO) within each group separately, where
the levels were taken to be 1 standard deviation above and below the mean values of EYO. The two EYO
subgroups were labelled "near" and "far", with "near" for EYO values close to zero (i.e. participant's age is
"near" the age at which disease symptoms were demonstrated in the family), and "far" for EYO being a
largely negative value (i.e. participant's age is "far" from the age at which disease symptoms were
demonstrated in the family). The analysis indicated that as the EYO decreases (i.e. participant's age is
reaching the years of onset of symptoms) the relationship between functional connectivity and
performance becomes stronger (moderation effects: r=.14, p=.021 and r=.28, p<.001 for NC and PSC,
respectively). Interestingly this relationship was stronger in each EYO subgroup for PSC relative to NC (PSC-
Near vs NC-Near: r=.28, p<.001; PSC-Far vs NC-Far: r=.22, p=.001). These findings indicate that the
relationship between FC and cognition is stronger in PSC relative to NC, and that this relationship increases
as a function of EYO.

4. Discussion

In the present study, we confirmed previous findings of group differences in brain structure and function,
in the absence of differences in cognitive performance between non-carriers and presymptomatic carriers

of FTD-related genetic mutations. But, while the relationship between structure and cognition was similar
in both groups, the coupling between function and cognition was stronger for presymptomatic carriers,
and increased as they approached the expected onset of disease.

These results suggest that people can maintain good cognitive abilities and successful day-to-day
functioning despite significant neuronal loss and atrophy. This disjunction between structure and function
is a feature of healthy ageing, but we have shown that it also characterises presymptomatic FTD, over and
above the age effects in their other family members, despite widespread progressive atrophy. The
multivariate approach reveals two key findings: (i) presymptomatic carriers express stronger between-
network and weaker within-network functional connectivity than age-matched non-carriers, and (ii) as
carriers approach their estimated age of symptom onset, and atrophy becomes evident, the maintenance
of good cognition is increasingly associated with sustaining balance of within- and between-network
integration.

This balance of within- and between-network connectivity is characteristic of segregated and specialized
network organization of brain systems. Such functional segregation varies with physiological ageing
[17,18,37], with cognitive function [18] and in individuals at risk for Alzheimer's disease [38]. Graph-
theoretic quantification of network organisation confirms the relevance of modularity and efficiency to
function in FTD [16]. Conversely, the loss of neural systems' modularity mirrors the loss of functional
specialization with age [39] and dementia [38]. Here, we show the significance of the maintenance of this
functional network organisation, with a progressively stronger correlation with cognitive performance as
seemingly healthy adults approach the age of expected onset of FTD.

The uncoupling of brain function from brain structure indicates that there may be independent and
synergistic effects of multiple factors leading to cognitive preservation. This is consistent with a previous
work in healthy ageing where brain activity and connectivity provide independent and synergistic
predictions of performance across the lifespan [19]. Therefore, future studies need to consider the
independent and synergistic effects of many possible biomarkers, based on MRI, computed tomography,
positron-emission tomography, CSF, blood and brain histopathology. For example, functional network
impairment may be related to tau expression and tau pathology, amyloid load, or neurotransmitter deficits
in neurodegenerative diseases, independent of atrophy [29,40–42]. Importantly, studies need to recognise
the rich multivariate nature of cognition and of neuroimaging in order to improve stratification procedures,
e.g. based on integrative approaches that explain individual differences in cognitive impairment [29,43].

We also recognise the difficulty to determine a unique contribution of each factor (e.g. brain structure and

brain function), given the increasing interaction between factors in advanced stages of disease [44]. This is

further complicated by these alterations becoming irreversible with progression of neurodegeneration

[45]. This suggests that the critical interplay between multiple factors (including brain structure and

function) may be better studied in the asymptomatic and preclinical stages as well as across the healthy

lifespan, which could still be modifiable and their influences are likely to be more separable.

Our findings agree with the model of compensation in the presymptomatic and early phases of

Huntington's disease, where network coupling predicted better cognitive performance [46]. In a recent

longitudinal study a non-linear concave-down pattern of both brain activity and behaviour was present,

despite a linear decline in brain volume over time, [47]. Similar effects have been observed also in healthy

ageing and amnestic mild cognitive impairment, where greater connectivity with the default-mode network

and weaker connectivity between default-mode network and dorsal-attention network was associated with

higher cognitive status in both groups [48]. Network integrity may also play a role in compensatory

mechanisms in non-cognitive symptoms, such as motor impairment in Parkinson's disease [49].

Accordingly, increased network efficiency and connectivity has been shown in prodromal phases, followed

by decreased local connectivity in symptomatic phases, suggesting the emergence and dissipation of neural

compensation [50].

The current study has several limitations. First, despite the large sample of subjects included, we did not

analyse each gene separately, as it may have resulted in too small and unbalanced samples, lowering

statistical power and robustness. Moreover, genetic FTD is also characterised by multiple mutations within

these genes and pleiotropy of clinical phenotypes even for the same mutation [10]. Pleiotropy in terms of

clinical phenotype is avoided by the study of presymptomatic carriers, but we cannot rule out pleiotropy

of intermediate phenotypes expressed as say neural network diversity. Furthermore, clinical heterogeneity

is modified by environmental factors such as education [which may be a surrogate of cognitive reserve, 51],

in FTD as in other dementias [12]. Genetic modifiers such as TMEM106B [52], APOE [53], have also been

identified. Further work, with larger cohorts, will be able to test the potential effect of these moderators

on the relationships between brain structure, functional networks and cognition. Future studies will benefit

from using brain measures that reflect differences in neural connectivity directly from neurophysiology or

separation of neurovascular from neuronal contributors to BOLD fMRI variance [18,54], which can

confound the effects of age, drug or disease [55].

The current study is cross-sectional. Therefore, we cannot infer longitudinal progression within subjects as

the unambiguous cause of the effects we observe in relation to expected years of onset. Accumulating

evidence suggests that network integrity serves to maintain performance with either physiological ageing

or pathological conditions. However, longitudinal mediation studies and pharmacological or electroceutical

interventions would be needed to prove its causal role in cognitive preservation. Finally, our findings are

limited to autosomal dominant FTD, which represents a minority of FTD: generalisation to sporadic forms

of disease would be speculative.

In conclusion, we used a multivariate data-driven approach to demonstrate that brain functional integrity

can enable presymptomatic carriers to maintain cognitive performance in the presence of progressive brain

atrophy for years before the onset of symptoms. The approach and the findings have implications for the

design of presymptomatic disease-modifying therapy trials and the study of unique and synergistic effects

of risk factors and biomarkers in health and disease, which are otherwise increasingly interacting and

irreversible with progression of neurodegeneration.

5. References

[1]   Persson J, Nyberg L, Lind J, Larsson A, Nilsson LG, Ingvar M, et al. Structure-function correlates of cognitive decline in aging. CerebCortex 2006;16:907–15.

[2]   Geerligs L, Cam-CAN, Henson RN. Functional connectivity and structural covariance between regions of interest can be measured more accurately using multivariate distance correlation. Neuroimage 2016;135:16–31. doi:10.1016/j.neuroimage.2016.04.047.

[3]   Cope TE, Rittman T, Borchert RJ, Jones PS, Vatansever D, Allinson K, et al. Tau burden and the functional connectome in Alzheimer's disease and progressive supranuclear palsy. Brain 2018;141:550–67. doi:10.1093/brain/awx347.

[4]   Seeley WW, Crawford RK, Zhou J, Miller BL, Greicius MD. Neurodegenerative diseases target large-scale human brain networks. Neuron 2009;62:42–52. doi:10.1016/j.neuron.2009.03.024.

[5]   Raj A, Kuceyeski A, Weiner M. A network diffusion model of disease progression in dementia. Neuron 2012;73:1204–15. doi:10.1016/j.neuron.2011.12.040.

[6]   Kinnunen KM, Cash DM, Poole T, Frost C, Benzinger TLS, Ahsan RL, et al. Presymptomatic atrophy in autosomal dominant Alzheimer's disease: A serial magnetic resonance imaging study. Alzheimer's Dement 2018;14:43–53. doi:10.1016/j.jalz.2017.06.2268.

[7]   Rohrer JD, Nicholas JM, Cash DM, van Swieten J, Dopper E, Jiskoot L, et al. Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal dementia Initiative (GENFI) study: a cross-sectional analysis. Lancet Neurol 2015;14:253–62. doi:10.1016/S1474-4422(14)70324-2.

[8]   Vatsavayai SC, Yoon SJ, Gardner RC, Gendron TF, Vargas JNS, Trujillo A, et al. Timing and significance of pathological features in *C9orf72* expansion-associated frontotemporal dementia. Brain 2016;139:3202–16. doi:10.1093/brain/aww250.

[9]   Deleon J, Miller BL. Frontotemporal dementia, 2018, p. 409–30. doi:10.1016/B978-0-444-64076-5.00027-2.

[10] Snowden JS, Adams J, Harris J, Thompson JC, Rollinson S, Richardson A, et al. Distinct clinical and
pathological phenotypes in frontotemporal dementia associated with MAPT, PGRN and C9orf72
mutations. Amyotroph Lateral Scler Front Degener 2015;16:497–505.
doi:10.3109/21678421.2015.1074700.

[11] Murphy NA, Arthur KC, Tienari PJ, Houlden H, Chiò A, Traynor BJ. Age-related penetrance of the
C9orf72 repeat expansion. Sci Rep 2017;7:2116. doi:10.1038/s41598-017-02364-1.

[12] Premi E, Grassi M, Van Swieten J, Galimberti D, Graff C, Masellis M, et al. Cognitive reserve and
TMEM106B genotype modulate brain damage in presymptomatic frontotemporal dementia: a
GENFI study. Brain 2017;140:1784–91. doi:10.1093/brain/awx103.

[13] Cash DM, Bocchetta M, Thomas DL, Dick KM, van Swieten JC, Borroni B, et al. Patterns of gray
matter atrophy in genetic frontotemporal dementia: results from the GENFI study. Neurobiol Aging
2018;62:191–6. doi:10.1016/j.neurobiolaging.2017.10.008.

[14] Olm CA, McMillan CT, Irwin DJ, Van Deerlin VM, Cook PA, Gee JC, et al. Longitudinal structural gray
matter and white matter MRI changes in presymptomatic progranulin mutation carriers.
NeuroImage Clin 2018;19:497–506. doi:10.1016/J.NICL.2018.05.017.

[15] Floeter MK, Danielian LE, Braun LE, Wu T. Longitudinal diffusion imaging across the *C9orf72* clinical
spectrum. J Neurol Neurosurg Psychiatry 2018;89:53–60. doi:10.1136/jnnp-2017-316799.

[16] Rittman DT, Borchert MR, Jones MS, van Swieten J, Borroni B, Galimberti D, et al. Functional
network resilience to pathology in presymptomatic genetic frontotemporal dementia. Neurobiol
Aging 2019;77:169–77. doi:10.1016/J.NEUROBIOLAGING.2018.12.009.

[17] Chan MY, Park DC, Savalia NK, Petersen SE, Wig GS. Decreased segregation of brain systems across
the healthy adult lifespan. Proc Natl Acad Sci 2014;111:4997–5006.
doi:10.1073/pnas.1415122111.

[18] Tsvetanov KA, Henson RNA, Tyler LK, Razi A, Geerligs L, Ham TE, et al. Extrinsic and intrinsic brain
network connectivity maintains cognition across the lifespan despite accelerated decay of regional
brain activation. J Neurosci 2016;36:3115–26. doi:10.1523/JNEUROSCI.2733-15.2016.

[19] Tsvetanov KA, Ye Z, Hughes L, Samu D, Treder MS, Wolpe N, et al. Activity and connectivity
differences underlying inhibitory control across the adult lifespan. J Neurosci 2018;38:7887–900.

doi:10.1523/JNEUROSCI.2919-17.2018.

[20]   Chhatwal JP, Schultz AP, Johnson KA, Hedden T, Jaimes S, Benzinger TLS, et al. Preferential degradation of cognitive networks differentiates Alzheimer's disease from ageing. Brain 2018;141:1486–500. doi:10.1093/brain/awy053.

[21]   Shafto MA, Tyler LK, Dixon M, Taylor JR, Rowe JB, Cusack R, et al. The Cambridge Centre for Ageing and Neuroscience (Cam-CAN) study protocol: a cross-sectional, lifespan, multidisciplinary examination of healthy cognitive ageing. BMC Neurol 2014;14:204. doi:10.1186/s12883-014-0204-1.

[22]   Morris JC, Weintraub S, Chui HC, Cummings J, DeCarli C, Ferris S, et al. The Uniform Data Set (UDS): Clinical and Cognitive Variables and Descriptive Data From Alzheimer Disease Centers. Alzheimer Dis Assoc Disord 2006;20:210–6. doi:10.1097/01.wad.0000213865.09806.92.

[23]   Ashburner J. A fast diffeomorphic image registration algorithm. Neuroimage 2007;38:95–113. doi:10.1016/j.neuroimage.2007.07.007.

[24]   Cusack R, Vicente-Grabovetsky A, Mitchell DJ, Wild CJ, Auer T, Linke AC, et al. Automatic analysis (aa): efficient neuroimaging workflows and parallel processing using Matlab and XML. Front Neuroinform 2014;8:90. doi:10.3389/fninf.2014.00090.

[25]   Friston KJ, Ashburner J, Kiebel S, Nichols T, Penny WD. Statistical parametric mapping : the analysis of funtional brain images. Elsevier Academic Press; 2007.

[26]   Jenkinson M, Bannister P, Brady M, Smith S. Improved optimization for the robust and accurate linear registration and motion correction of brain images. Neuroimage 2002;17:825–41.

[27]   Pruim RHR, Mennes M, Buitelaar JK, Beckmann CF. Evaluation of ICA-AROMA and alternative strategies for motion artifact removal in resting state fMRI. Neuroimage 2015;112:278–87. doi:10.1016/j.neuroimage.2015.02.063.

[28]   Geerligs L, Tsvetanov KA, Cam-Can, Henson RN. Challenges in measuring individual differences in functional connectivity using fMRI: The case of healthy aging. Hum Brain Mapp 2017. doi:10.1002/hbm.23653.

[29]   Passamonti L, Tsvetanov KA, Jones PS, Bevan-Jones WR, Arnold R, Borchert RJ, et al.

Neuroinflammation and functional connectivity in Alzheimer's disease: interactive influences on

cognitive performance. BioRxiv Prepr 2019. doi:10.1101/532291.

[30] Shirer WR, Ryali S, Rykhlevskaia E, Menon V, Greicius MD. Decoding subject-driven cognitive states

with whole-brain connectivity patterns. Cereb Cortex 2012;22:158–65.

doi:10.1093/cercor/bhr099.

[31] Blankertz B, Lemm S, Treder M, Haufe S, Müller K-R. Single-trial analysis and classification of ERP

components--a tutorial. Neuroimage 2011;56:814–25. doi:10.1016/j.neuroimage.2010.06.048.

[32] Ledoit O, Wolf M. A well-conditioned estimator for large-dimensional covariance matrices. J

Multivar Anal 2004;88:365–411. doi:10.1016/S0047-259X(03)00096-4.

[33] Lemm S, Blankertz B, Dickhaus T, Müller K-R. Introduction to machine learning for brain imaging.

Neuroimage 2011;56:387–99. doi:10.1016/j.neuroimage.2010.11.004.

[34] Fan L, Li H, Zhuo J, Zhang Y, Wang J, Chen L, et al. The Human Brainnetome Atlas: A New Brain Atlas

Based on Connectional Architecture. Cereb Cortex 2016;26:3508–26. doi:10.1093/cercor/bhw157.

[35] Krishnan A, Williams LJ, McIntosh AR, Abdi H. Partial Least Squares (PLS) methods for

neuroimaging: A tutorial and review. Neuroimage 2011;56:455–75.

doi:10.1016/j.neuroimage.2010.07.034.

[36] Dawson JF, Richter AW. Probing three-way interactions in moderated multiple regression:

Development and application of a slope difference test. J Appl Psychol 2006;91:917–26.

doi:10.1037/0021-9010.91.4.917.

[37] Samu D, Campbell KL, Tsvetanov KA, Shafto MA, Consortium C-C, Brayne C, et al. Preserved

cognitive functions with age are determined by domain-dependent shifts in network responsivity.

Nat Commun 2017;8:ncomms14743. doi:10.1038/ncomms14743.

[38] Contreras JA, Goñi J, Risacher SL, Amico E, Yoder K, Dzemidzic M, et al. Cognitive complaints in

older adults at risk for Alzheimer's disease are associated with altered resting-state networks.

Alzheimer's Dement Diagnosis, Assess Dis Monit 2017;6:40–9. doi:10.1016/J.DADM.2016.12.004.

[39] Cabeza R, Albert M, Belleville S, Craik FIM, Duarte A, Grady CL, et al. Maintenance, reserve and

compensation: the cognitive neuroscience of healthy ageing. Nat Rev Neurosci 2018;19:701–10.

doi:10.1038/s41583-018-0068-2.

[40]   Hedden T, Van Dijk KRA, Becker JA, Mehta A, Sperling RA, Johnson KA, et al. Disruption of functional
connectivity in clinically normal older adults harboring amyloid burden. J Neurosci 2009;29:12686–
94. doi:10.1523/JNEUROSCI.3189-09.2009.

[41]   Murley AG, Rowe JB. Neurotransmitter deficits from frontotemporal lobar degeneration. Brain
2018;141:1263–85. doi:10.1093/brain/awx327.

[42]   Rittman T, Rubinov M, Vértes PE, Patel AX, Ginestet CE, Ghosh BCP, et al. Regional expression of
the MAPT gene is associated with loss of hubs in brain networks and cognitive impairment in
Parkinson disease and progressive supranuclear palsy. Neurobiol Aging 2016;48:153–60.
doi:10.1016/J.NEUROBIOLAGING.2016.09.001.

[43]   Geerligs L, Tsvetanov KAKA. The use of resting state data in an integrative approach to studying
neurocognitive ageing – Commentary on Campbell and Schacter (2016). Lang Cogn Neurosci
2016;32. doi:http://dx.doi.org/10.1080/23273798.2016.1251600.

[44]   Vemuri P, Lesnick TG, Przybelski SA, Knopman DS, Preboske GM, Kantarci K, et al. Vascular and
amyloid pathologies are independent predictors of cognitive decline in normal elderly. Brain
2015;138:761–71. doi:10.1093/brain/awu393.

[45]   Rodrigue KM, Kennedy KM, Devous MD, Rieck JR, Hebrank AC, Diaz-Arrastia R, et al. β-Amyloid
burden in healthy aging: regional distribution and cognitive consequences. Neurology
2012;78:387–95. doi:10.1212/WNL.0b013e318245d295.

[46]   Klöppel S, Gregory S, Scheller E, Minkova L, Razi A, Durr A, et al. Compensation in Preclinical
Huntington's Disease: Evidence From the Track-On HD Study. EBioMedicine 2015;2:1420–9.
doi:10.1016/j.ebiom.2015.08.002.

[47]   Gregory S, Long JD, Klöppel S, Razi A, Scheller E, Minkova L, et al. Operationalizing compensation
over time in neurodegenerative disease. Brain 2017;140:1158–65. doi:10.1093/brain/awx022.

[48]   Sullivan MD, Anderson JAE, Turner GR, Spreng RN. Intrinsic neurocognitive network connectivity
differences between normal aging and mild cognitive impairment are associated with cognitive
status and age. Neurobiol Aging 2019;73:219–28. doi:10.1016/J.NEUROBIOLAGING.2018.10.001.

[49] Blesa J, Trigo-Damas I, Dileone M, del Rey NL-G, Hernandez LF, Obeso JA. Compensatory
mechanisms in Parkinson's disease: Circuits adaptations and role in disease modification. Exp
Neurol 2017;298:148–61. doi:10.1016/J.EXPNEUROL.2017.10.002.

[50] Wen M-C, Heng HSE, Hsu J-L, Xu Z, Liew GM, Au WL, et al. Structural connectome alterations in
prodromal and de novo Parkinson's disease patients. Parkinsonism Relat Disord 2017;45:21–7.
doi:10.1016/j.parkreldis.2017.09.019.

[51] Stern Y. Cognitive reserve in ageing and Alzheimer's disease. Lancet Neurol 2012;11:1006–12.
doi:10.1016/S1474-4422(12)70191-6.

[52] Lattante S, Le Ber I, Galimberti D, Serpente M, Rivaud-Péchoux S, Camuzat A, et al. Defining the
association of TMEM106B variants among frontotemporal lobar degeneration patients with GRN
mutations and C9orf72 repeat expansions. Neurobiol Aging 2014;35:2658.e1-2658.e5.
doi:10.1016/J.NEUROBIOLAGING.2014.06.023.

[53] Koriath C, Kenny J, Adamson G, Druyeh R, Taylor W, Beck J, et al. Predictors for a dementia gene
mutation based on gene-panel next-generation sequencing of a large dementia referral series. Mol
Psychiatry 2018. doi:10.1038/s41380-018-0224-0.

[54] Sami S, Williams N, Hughes LE, Cope TE, Rittman T, Coyle-Gilchrist ITS, et al. Neurophysiological
signatures of Alzheimer's disease and frontotemporal lobar degeneration: pathology versus
phenotype. Brain 2018;141:2500–10. doi:10.1093/brain/awy180.

[55] Campbell KL, Shafto MA, Wright P, Tsvetanov KA, Geerligs L, Cusack R, et al. Idiosyncratic
responding during movie-watching predicted by age differences in attentional control. Neurobiol
Aging 2015;36:3045–55. doi:10.1016/j.neurobiolaging.2015.07.028.

6. Acknowledgements

522   Kamen A. Tsvetanov is supported by the British Academy (Postdoctoral Fellowship, PF160048).

523 James B Rowe is supported by the Wellcome Trust (103838) the Medical Research Council (SUAG/051

524 G101400) and the Cambridge NIHR Biomedical Research Centre. Raquel Sánchez-Valle is supported by the

525 Instituto de Salud Carlos III and the JPND network PreFrontAls (01ED1512/AC14/0013) and the Fundació

526 Marató de TV3 (20143810).

7. Tables

530   *Table 1. Demographics of participants included in the analysis, grouped by genetic status*
531   *as non-carriers (NC) and presymptomatic carriers (PSC). * denotes whether demographics vary*
532   *between NC and PSC groups.*

		Gene Carrier Group		Statistical tests*	
		NC	PSC	X^2 or F-test	*P*-value
N		134	121		
Age				2.68	0.103
	Mean / SD	49 / 14	46 / 11		
	Range [Min/Max]	19 / 86	20 / 70		
Gender, n (%)				0.01	0.908
	Men	53 (39.6)	47 (38.8)		
	Women	81 (60.4)	74 (61.2)		
Expected Years to Onset				0.23	0.631
	Mean / SD	-10 / 12	-11 / 11		
	Range [Min/Max]	-25 / 10	-25 / 10		
Education				0.05	0.826
	Mean / SD	14 / 3	14 / 3		
	Range [Min/Max]	5 / 24	5 / 22		
Mini-Mental State Examination				0.39	0.532
	Mean / SD	29 / 1	29 / 1		
	Range [Min/Max]	25 / 30	23 / 30		

8. Figures

Figure 1. Schematic representation of data processing and analysis pipeline to test for brain-behaviour differences between presymptomatic carriers (PSC) and non-carriers (NC) as a function of expected years to onset (EYO) of symptoms, while controlling for covariates of no interest (Covs). Brain structural measures were based on the mean grey matter volume (GMV) in 246 nodes, as defined in the Brainnetome atlas [34]. Brain functional measures were based on the functional connectivity between 15 nodes as part of four large-scale networks, which were defined in an independent cohort of 298 age-matched individuals part of the Cam-CAN dataset (Passamonti et al 2019 BioArxiv).

Figure 2. Visualisation of spatial localisation of the nodes part of the four large-scale networks and their mean functional connectivity (circular plot) across all participants in this study. Nodes and networks were defined in an independent cohort of 298 age-matched individuals part of the Cam-CAN dataset (Passamonti et al 2019).The default mode network (DMN) contained five nodes: the ventral anterior cingulate cortex (vACC), dorsal and ventral posterior cingulate cortex (vPCC and dPCC), and right and left inferior parietal lobes (rIPL and lIPL). The salience network (SN) was defined using right and left anterior insular (rAI and lAI) and dorsal anterior cingulate cortex (dACC). The frontoparietal network (FPN) was defined using right and left anterior superior frontal gyrus (raSFG and laSFG), and right and left angular gyrus (rAG and lAG). The dorsal attention Network (DAN) was defined using right and left intraparietal sulcus (rIPS and lIPS).

560   *Figure 3. Group differences between PSC and NC in grey matter volume (left panel) and*
561 *functional connectivity between nodes within four large scale networks (right panel). Hot colour*
562 *scheme indicates the strength of effect size of PSC showing higher GMV and FC than NC, while cold*
563 *colour scheme indicates the opposite effect (i.e. NC > PSC).*

Figure 4. PLS analysis of grey matter volume (GMV) and cognition indicating the spatial distribution of GMV loading values (a), where hot and cold colour schemes are used for the strength of positive and negative correlations with the profile of Cognitive LV (b). (c) The scatter plot on the left represents the relationship between subjects scores of GMV LV and Cognition LV for presymptomatic carriers (PSC) and non-carriers (NC). The scatter plots in the middle and right hand-side represent GMV-Cognition LV relationship as a function of expected years to onset (EYO, split in two groups, Near and Far, see text) in each gene group separately.

Figure 5. *PLS analysis of functional connectivity and cognition indicating the connectivity pattern of loading values (a), where hot and cold colour schemes are used for the strength of positive and negative correlations with the profile of Cognitive LV (b). (c) The scatter plot on the left represents the relationship between subjects scores of Function LV and Cognition LV for presymptomatic carriers (PSC) and non-carriers (NC). The scatter plots in the middle and right hand-side represents Function-Cognition LV relationship as a function of expected years to onset (EYO split in two groups, Near and Far, see text) in each gene group separately, which is also represented using a bar chart in (d). * denotes significant test at p-value < 0.05.*

9. APPENDIX

List of other GENFI consortium members

Sónia Afonso - Instituto Ciencias Nucleares Aplicadas a Saude, Universidade de Coimbra, Coimbra, Portugal

Maria Rosario Almeida - Centre of Neurosciences and Cell Biology, Universidade de Coimbra, Coimbra, Portugal

Sarah Anderl-Straub – Department of Neurology, Ulm University, Ulm, GermanyChristin Andersson - Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden

Anna Antonell - Alzheimer's disease and other cognitive disorders unit, Neurology Department, Hospital Clinic, Institut d'Investigacions Biomèdiques, Barcelona, Spain

Silvana Archetti - Biotechnology Laboratory, Department of Diagnostics, Spedali Civili Hospital, Brescia, Italy

Andrea Arighi - Fondazione IRCSS Ca' Granda, Ospedale Maggiore Policlinico, Neurodegenerative Diseases Unit, Milan, Italy

Mircea Balasa - Alzheimer's disease and other cognitive disorders unit, Neurology Department, Hospital Clinic, Institut d'Investigacions Biomèdiques, Barcelona, Spain

Myriam Barandiaran - Neuroscience Area, Biodonostia Health Research Institute, Paseo Dr Begiristain sn, CP 20014, San Sebastian, Gipuzkoa, Spain

Nuria Bargalló - Radiology Department, Image Diagnosis Center, Hospital Clínic and Magnetic Resonance Image core facility, IDIBAPS, Barcelona, Spain

Robart Bartha - Department of Medical Biophysics, Robarts Research Institute, University of Western Ontario, London, Ontario, Canada

Benjamin Bender - Department of Diagnostic and Interventional Neuroradiology, University of Tuebingen, Tuebingen, Germany

Luisa Benussi - Istituto di Ricovero e Cura a Carattere Scientifico Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy

Valentina Bessi - Department of Neuroscience, Psychology, Drug Research, and Child Health, University of Florence, Florence, Italy

Giuliano Binetti - Istituto di Ricovero e Cura a Carattere Scientifico Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy

Sandra Black - LC Campbell Cognitive Neurology Research Unit, Sunnybrook Research Institute, Toronto, Canada

Martina Bocchetta – Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square London, UK

Sergi Borrego-Ecija - Alzheimer's disease and other cognitive disorders unit, Neurology Department, Hospital Clinic, Institut d'Investigacions Biomèdiques, Barcelona, Spain

Jose Bras – Dementia Research Institute, Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK

Rose Bruffaerts - Laboratory for Cognitive Neurology, Department of Neurosciences, KU Leuven, Leuven, Belgium

Paola Caroppo - Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Neurologico Carlo Besta, Milan, Italy

David Cash – Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK

Miguel Castelo-Branco - Neurology Department, Centro Hospitalar e Universitário de Coimbra, Instituto de Ciências Nucleares Aplicadas à Saúde (ICNAS), Coimbra, Portugal

Rhian Convery – Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK

Thomas Cope – Department of Clinical Neuroscience, University of Cambridge, Cambridge, UK

Maura Cosseddu – Centre for Neurodegenerative Disorders, Neurology Unit, Spedali Civili Hospital, Brescia, Italy

María de Arriba - Neuroscience Area, Biodonostia Health Research Institute, Paseo Dr Begiristain sn, CP 20014, San Sebastian, Gipuzkoa, Spain

Giuseppe Di Fede - Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Neurologico Carlo Besta, Milan, Italy

Zigor Díaz - CITA Alzheimer, San Sebastian, Spain

Katrina M Moore – Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of
Neurology, Queen Square, London, UK
Diana Duro - Faculty of Medicine, Universidade de Coimbra, Coimbra, Portugal
Chiara Fenoglio - University of Milan, Centro Dino Ferrari, Milan, Italy
Camilla Ferrari - Department of Neuroscience, Psychology, Drug Research, and Child Health, University of Florence,
Florence, Italy
Carlos Ferreira - Instituto Ciências Nucleares Aplicadas à Saúde, Universidade de Coimbra, Coimbra, Portugal
Catarina B. Ferreira - Faculty of Medicine, University of Lisbon, Lisbon, Portugal
Toby Flanagan – Faculty of Biology, Medicine and Health, Division of Neuroscience and Experimental Psychology,
University of Manchester, Manchester, UK
Nick Fox – Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology,
Queen Square, London, UK
Morris Freedman - Division of Neurology, Baycrest Centre for Geriatric Care, University of Toronto, Toronto, Canada
Giorgio Fumagalli - Fondazione IRCSS Ca' Granda, Ospedale Maggiore Policlinico, Neurodegenerative Diseases Unit,
Milan, Italy; Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence,
Florence, Italy
Alazne Gabilondo - Neuroscience Area, Biodonostia Health Research Institute, Paseo Dr Begiristain sn, CP 20014, San
Sebastian, Gipuzkoa, Spain
Roberto Gasparotti - Neuroradiology Unit, University of Brescia, Brescia, Italy
Serge Gauthier - Department of Neurology and Neurosurgery, McGill University, Montreal, Québec, Canada
Stefano Gazzina - Centre for Neurodegenerative Disorders, Neurology Unit, Department of Clinical and Experimental
Sciences, University of Brescia, Brescia, Italy
Giorgio Giaccone - Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Neurologico Carlo Besta,
Milan, Italy
Ana Gorostidi - Neuroscience Area, Biodonostia Health Research Institute, Paseo Dr Begiristain sn, CP 20014, San
Sebastian, Gipuzkoa, Spain
Caroline Greaves – Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of
Neurology, Queen Square London, UK
Rita Guerreiro – Dementia Research Institute, Department of Neurodegenerative Disease, UCL Institute of
Neurology, London, UK
Carolin Heller – Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology,
Queen Square, London, UK
Tobias Hoegen - Department of Neurology, Ludwig-Maximilians-University of Munich, Munich, Germany
Begoña Indakoetxea - Cognitive Disorders Unit, Department of Neurology, Donostia University Hospital, Paseo Dr
Begiristain sn, CP 20014, San Sebastian, Gipuzkoa, Spain
Vesna Jelic - Division of Clinical Geriatrics, Karolinska Institutet, Stockholm, Sweden
Lize Jiskoot - Department of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands
Hans-Otto Karnath - Section of Neuropsychology, Department of Cognitive Neurology, Center for Neurology &
Hertie-Institute for Clinical Brain Research, Tübingen, Germany
Ron Keren - University Health Network Memory Clinic, Toronto Western Hospital, Toronto, Canada
Maria João Leitão - Centre of Neurosciences and Cell Biology, Universidade de Coimbra, Coimbra, Portugal
Albert Lladó - Alzheimer's disease and other cognitive disorders unit, Neurology Department, Hospital Clinic, Institut
d'Investigacions Biomèdiques, Barcelona, Spain
Gemma Lombardi - Department of Neuroscience, Psychology, Drug Research and Child Health, University of
Florence, Florence, Italy
Sandra Loosli - Department of Neurology, Ludwig-Maximilians-University of Munich, Munich, Germany
Carolina Maruta - Lisbon Faculty of Medicine, Language Research Laboratory, Lisbon, Portugal
Simon Mead - MRC Prion Unit, Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen
Square, London, UK
Lieke Meeter - Department of Neurology, Erasmus Medical Center, Rotterdam, Netherlands
Gabriel Miltenberger - Faculty of Medicine, University of Lisbon, Lisbon, Portugal
Rick van Minkelen - Department of Clinical Genetics, Erasmus Medical Center, Rotterdam, The Netherlands
Sara Mitchell - LC Campbell Cognitive Neurology Research Unit, Sunnybrook Research Institute, Toronto, Canada

Benedetta Nacmias - Department of Neuroscience, Psychology, Drug Research and Child Health, University of
Florence, Florence, Italy
Mollie Neason - Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology,
Queen Square, London, UK
Jennifer Nicholas – Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, UK
Linn Öijerstedt - Department of Geriatric Medicine, Karolinska Institutet, Stockholm, Sweden
Jaume Olives - Alzheimer's disease and other cognitive disorders unit, Neurology Department, Hospital Clinic, Institut
d'Investigacions Biomèdiques, Barcelona, Spain
Alessandro Padovani - Centre for Neurodegenerative Disorders, Neurology Unit, Department of Clinical and
Experimental Sciences, University of Brescia, Brescia, Italy
Jessica Panman – Department of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands
Janne Papma - Department of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands
Irene Piaceri - Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence,
Florence
Michela Pievani - Istituto di Ricovero e Cura a Carattere Scientifico Istituto Centro San Giovanni di Dio
Fatebenefratelli, Brescia, Italy
Yolande Pijnenburg - VUMC, Amsterdam, The Netherlands
Cristina Polito - Department of Biomedical, Experimental and Clinical Sciences "Mario Serio", Nuclear Medicine Unit,
University of Florence, Florence, Italy
Enrico Premi - Stroke Unit, Neurology Unit, Spedali Civili Hospital, Brescia, Italy
Sara Prioni - Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Neurologico Carlo Besta, Milan,
Italy
Catharina Prix - Department of Neurology, Ludwig-Maximilians-University Munich, Germany
Rosa Rademakers - Department of Neurosciences, Mayo Clinic, Jacksonville, Florida, USA
Veronica Redaelli - Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Neurologico Carlo Besta,
Milan, Italy
Tim Rittman – Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK
Ekaterina Rogaeva - Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto,
Canada
Pedro Rosa-Neto - Translational Neuroimaging Laboratory, McGill University Montreal, Québec, Canada
Giacomina Rossi - Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Neurologico Carlo Besta,
Milan, Italy
Martin Rossor – Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology,
Queen Square, London, UK
Beatriz Santiago - Neurology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
Elio Scarpini - University of Milan, Centro Dino Ferrari, Milan, Italy; Fondazione IRCSS Ca' Granda, Ospedale Maggiore
Policlinico, Neurodegenerative Diseases Unit, Milan, Italy
Sonja Schönecker - Neurologische Klinik, Ludwig-Maximilians-Universität München, Munich, Germany
Elisa Semler – Department of Neurology, Ulm University, Ulm, Germany
Rachelle Shafei – Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology,
Queen Square, London, UK
Christen Shoesmith - Department of Clinical Neurological Sciences, University of Western Ontario, London, Ontario,
Canada
Miguel Tábuas-Pereira - Centre of Neurosciences and Cell Biology, Universidade de Coimbra, Coimbra, Portugal
Mikel Tainta - Neuroscience Area, Biodonostia Health Research Institute, Paseo Dr Begiristain sn, CP 20014, San
Sebastian, Gipuzkoa, Spain
Ricardo Taipa - Neuropathology Unit and Department of Neurology, Centro Hospitalar do Porto - Hospital de Santo
António, Oporto, Portugal
David Tang-Wai - University Health Network Memory Clinic, Toronto Western Hospital, Toronto, Canada
David L Thomas - Neuroradiological Academic Unit, UCL Institute of Neurology, London, UK
Hakan Thonberg - Center for Alzheimer Research, Division of Neurogeriatrics, Karolinska Institutet, Stockholm,
Sweden
Carolyn Timberlake - University of Cambridge, Cambridge, UK

Pietro Tiraboschi - Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Neurologico Carlo Besta,
Milano, Italy
Philip Vandamme - Neurology Service, University Hospitals Leuven, Belgium; Laboratory for Neurobiology, VIB-KU
Leuven Centre for Brain Research, Leuven, Belgium
Mathieu Vandenbulcke - Geriatric Psychiatry Service, University Hospitals Leuven, Belgium; Neuropsychiatry,
Department of Neurosciences, KU Leuven, Leuven, Belgium
Michele Veldsman - University of Oxford, UK
Ana Verdelho - Department of Neurosciences, Santa Maria Hospital, University of Lisbon, Portugal
Jorge Villanua - OSATEK Unidad de Donostia, San Sebastian, Gipuzkoa, Spain
Jason Warren – Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology,
Queen Square, London, UK
Carlo Wilke - Hertie Institute for Clinical Brain Research, University of Tuebingen, Tuebingen, Germany
Ione Woollacott – Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of
Neurology, Queen Square, London, UK
Elisabeth Wlasich - Neurologische Klinik, Ludwig-Maximilians-Universität München, Munich, Germany
Henrik Zetterberg - Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK
Miren Zulaica - Neuroscience Area, Biodonostia Health Research Institute, Paseo Dr Begiristain sn, CP 20014, San
Sebastian, Gipuzkoa, Spain.
755